

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 1/02, 1/06, 1/10 C07K 3/04, 3/06	A1	(11) International Publication Number: WO 93/25571 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/US93/05783 (22) International Filing Date: 16 June 1993 (16.06.93) (30) Priority data: 921942 16 June 1992 (16.06.92) IE (71)(72) Applicants and Inventors: SIWRUK, Gary, A. [US/US]; 1212 Franklin Crossing Road, Franklin, MA 02038 (US). EYNON, John, S. [US/US]; 30 Monique Drive, Bel- lingham, MA 02019 (US). (74) Agent: CLARK, Paul, T.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AU, CA, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: LIQUID PHASE SYNTHESIS OF PEPTIDES AND PEPTIDE DERIVATIVES (57) Abstract A liquid phase peptide synthetic method which uses (1) Fmoc as the protecting group for the non-side chain amino func- tionality, (2) ammonia, a primary or secondary amine to remove the Fmoc protecting group, and (3) substituted carbodiimide as the coupling agent for the C to N synthesis of peptides or peptide derivatives in a proper organic solvent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

BEST AVAILABLE COPY

- 1 -

LIQUID PHASE SYNTHESIS OF PEPTIDES
AND PEPTIDE DERIVATIVES

Background of the Invention

5 Classical liquid phase peptide synthesis involves the well-known problems of many manipulations and considerable loss of material during the isolation and purification of intermediates.

 Some of these problems have been circumvented by
10 using continuous liquid phase techniques. Furthermore, numerous advances made in solid phase peptide synthesis have led to progress in liquid phase synthetic methods. For example, the protecting groups developed in solid phase synthesis are also useful in liquid phase
15 synthesis.

 The two major routes in liquid phase synthesis are (1) use of the t-butyloxycarbonyl protecting group ("Boc") to block the non-side chain amino functionality, and (2) use of the 9-fluorenyl methoxycarbonyl
20 protecting group ("Fmoc") to block the same functionality. For examples, see Thierry, J. et al. J. Med. Chem. 33:2122 (1990) and Høeg-Jensen, T. et al. Tetrahedron Letters 32:6387 (1991).

 No continuous liquid phase peptide synthetic
25 methods using Fmoc as the protecting group and a substituted carbodiimide as the coupling agent have hitherto been reported.

Summary of the Invention

 The present invention relates to a continuous
30 liquid phase synthetic method for preparing a peptide containing 2-10 amino acid residues with or without modification at the C-terminus or an N-acyl derivative thereof, which method comprises the steps of:

- 2 -

(a) coupling a first amino acid or a derivative thereof to a second amino acid via an amide bond in an organic solvent containing a substituted carbodiimide, with the first amino acid or derivative thereof having
5 both its non-side chain carboxyl functionality and its side-chain functionalities, if any and necessary, blocked by base-stable groups and a second amino acid with its non-side chain amino functionality blocked by Fmoc and its side chain functionalities, if any and necessary,
10 blocked by base-stable groups;

(b) detaching the Fmoc with ammonia, a primary amine, or a secondary amine;

(c) coupling an additional amino acid to the Fmoc-detached coupled product via an amide bond in an organic
15 solvent containing a substituted carbodiimide, with the additional amino acid having its non-side chain amino functionality blocked by Fmoc and its side chain functionalities, if any and necessary, blocked by base-stable groups;

20 (d) detaching the Fmoc with ammonia, a primary amine, or a secondary amine;

(e) repeating steps (c) and (d) until the length of the peptide or the N-acyl derivative is achieved;

(f) acylating the non-side chain amino group of
25 the Fmoc-detached coupled product from the previous step; and

(g) detaching the base-stable groups;

In the above-described method, the first amino acid or derivative thereof corresponds to a first residue
30 (i.e., the C-terminal residue) in the peptide or its N-acyl derivative, the second amino acid corresponds to a second residue adjacent to the first residue in the peptide or its N-acyl derivative, and the additional amino acid corresponds to a third residue adjacent to the
35 second residue in the peptide or its N-acyl derivative.

- 3 -

(In other word, consecutive amide coupling is performed in the C terminus to N terminus direction with one amino acid linked to another based on the sequence of the peptide or its N-acyl derivative to be synthesized.)

5 Furthermore, when the peptide or the N-acyl derivative contains two amino acid residues, steps (c) through (e) are omitted. In addition, when the peptide, rather than the N-acyl derivative, is to be synthesized, step (f) is omitted.

10 Note that the carboxyl and amino groups which participate in the formation of an amide bond are called non-side chain functionalities. On the other hand, any functional groups which are not involved in formation of such a bond are called side chain functionalities.

15 A peptide without modification at the C-terminus refers to a peptide with a carboxylic group at its C-terminus (i.e., α -COOH of the C-terminal residue in most naturally-occurring peptides). A peptide with modification at the C-terminus, on the other hand, refers
20 to a peptide, which, instead of having a carboxylic group at its C-terminus as described above, possesses a C-terminal amide or substituted amide (i.e., CONH_2 or CONHR , where R is alkyl, arylalkyl or aryl), a C-terminal ester (i.e., COOR , where R is alkyl, arylalkyl or aryl),
25 or a C-terminal alcohol (i.e., CH_2OH).

What is meant by "an N-acyl derivative of a peptide" is a peptide with a hydrogen of its non-side chain amino functionality at the N-terminus replaced by an acyl chain containing 1 to 12 carbons, inclusive
30 (e.g., formyl, acetyl, benzoyl, hexanoyl, or naphthoyl).

What is meant by "an amino acid or derivative thereof" is an amino acid or its derivative. An amino acid derivative refers to an amino acid the carboxylic group of which (i.e., α -carboxyl in an α -amino acid
35 derivative) has been replaced by an amide or a

- 4 -

substituted amide, an ester, or an alcohol, as defined above; i.e., see the definition of a C-terminal amide or substituted amide, a C-terminal ester, or a C-terminal alcohol in a peptide with modification at its C-terminus.

5 Preferably, in the present synthetic method, the organic solvent used is methylene chloride, chloroform, dichloroethane, dimethylformamide, dimethylacetamide, tetrahydrofuran, ethyl acetate, acetonitrile, or a combination of the above solvents; the substituted
10 carbodiimide is diisopropylcarbodiimide, dicyclohexylcarbodiimide, or N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; the Fmoc is detached with 4-(aminomethyl)piperidine, piperidine, or tris (2-aminoethyl) amine; the detached Fmoc is removed by
15 filtration and subsequent washing with an acidic aqueous solution, e.g., a phosphate buffer, pH 5.5.

In a particular preferred embodiment, the organic solvent is methylene chloride and the Fmoc is detached with 4-aminomethylpiperidine.

20 It is also preferred that the base-stable groups be detached with trifluoroacetic acid in the synthetic method of this invention.

Further, where the N-acyl derivative is to be synthesized, it is preferable that a strong base, such as
25 triethylamine or diisopropylethylamine, be added in step (f).

Note that the term "base-stable group" refers to protecting groups used to obstruct functionalities of the amino acid building blocks which (1) are base stable,
30 i.e., cannot be removed by bases, such as 4-aminomethylpiperidine, piperidine, or tris (2-aminoethyl) amine, which are used to remove Fmoc, and (2) can be removed by an acid, such as trifluoroacetic acid, or by other means, such as catalytic hydrogenation. The symbol "Fmoc" is

- 5 -

used herein and in the appended claims to stand for the 9-fluoroenyl methoxycarbonyl group.

The above-described synthetic method can be used to prepare a tetrapeptide (e.g., H-Ser-Asp-Lys-Pro-OH) or
5 an N-acyl derivative of a tetrapeptide (e.g., Acetyl-Ser-Asp-Lys-Pro-OH). When H-Ser-Asp-Lys-Pro-OH or Acetyl-Ser-Asp-Lys-Pro-OH is to be synthesized, the base-stable protecting groups used to block the side chain
10 functionalities of Ser, Asp, Lys and Pro can be t-butyl, t-butyl, t-butyl-oxycarbonyl, and t-butyl, respectively.

In the formula H-Ser-Asp-Lys-Pro-OH, each of the conventional three-letter amino acid symbols (e.g., Ser) represents a structural residue. For example, the symbol Ser in the above formula stands for $\text{-NH-CH(CH}_2\text{OH)-CO-}$.
15 The formula Acetyl-Ser-Asp-Lys-Pro-OH stands for an N-acyl peptide derivative whose amino functionality (i.e., α -amino of Ser) is substituted with an acetyl group.

The above-described method is advantaged in that it uses substituted carbodiimides, which are rather
20 inexpensive, as the coupling agent and is thus most suitable for large-scale continuous liquid phase peptide synthesis. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

25 Brief Description of the Drawings

The drawings will first be briefly described.

Figure 1 is a scheme for synthesizing Acetyl-Ser-Asp-Lys-Pro-OH following a preferred method of the present invention.

30 Figure 2 is a high pressure liquid chromatograph of Acetyl-Ser-Asp-Lys-Pro-OH (purified product) prepared by the procedure shown in Figure 1, illustrating absorbance at 220 nm versus time.

- 6 -

Figure 3 is a high pressure liquid chromatograph of H-Ser-Asp-Lys-Pro-OH (crude product) prepared by a procedure similar to that shown in Figure 1, illustrating absorbance at 220 nm versus time.

5 Description of the Preferred Embodiments

The present invention is an improvement of the conventional liquid phase peptide synthetic method. In particular, it teaches the use of Fmoc as the protecting group for the non-side chain amino functionality, the use
10 of ammonia, a primary or secondary amine [e.g., 4-aminomethyl-piperidine, piperidine, or tris (2-aminoethyl) amine] to remove the Fmoc protecting group, and the use of a selected substituted carbodiimide [e.g., diisopropylcarbodiimide, dicyclohexylcarbodiimide, or N-ethyl-N'-(3-dimethyl-aminopropyl)carbodiimide] as the
15 coupling agent for the C terminus to N terminus synthesis of peptides in a proper organic solvent. Proper solvents include, but are not limited to, methylene chloride, chloroform, dichloroethane, dimethylformamide, and
20 combination thereof; minor modification of the procedures might be necessary in using different solvents.

The above teachings enable one to use washes with an acidic aqueous solution for removal of excess reagents or undesired products thereof. For example, when 4-
25 aminomethylpiperidine is used to remove Fmoc, any excess 4-aminomethylpiperidine, 9-(4'-aminomethylpiperidinylmethyl) fluorene (i.e., a 4-aminomethylpiperidine/Fmoc product), and the product from amino acid coupled to 4-aminomethylpiperidine can be
30 extracted by a phosphate buffer, pH 5.5. Furthermore, trace amounts of the coupling agent and its product can also be readily removed by the phosphate buffer.

According to the present invention, the by-products and excess reagents can also be removed by

- 7 -

filtration. For instance, when diisopropylcarbodiimide is used as the coupling agent, diisopropyl urea formed from it is partially soluble in methylene chloride, thus enabling one to remove the insoluble amount by filtration (e.g., vacuum filtration). The product from the reaction of 4-aminomethylpiperidine and the Fmoc group is also partially soluble in methylene chloride and some of it can likewise be removed by filtration. Such partial removal is preferred, since it reduces the chance of an emulsion forming upon addition of an aqueous solution for further extraction of excess reagents. Cooling is desired before filtration, since it generally further reduces the solubility of the partially soluble materials, and lowers the vapor pressure of the organic solvent, thus facilitating the subsequent vacuum filtration.

The above-described techniques, i.e., aqueous extraction and filtration to remove excess reagents and undesired products, are rather simple. Employment thereof enables one to eliminate the tedious and time-consuming steps of purifying intermediates chromatographically; such steps are used in the conventional liquid phase peptide synthesis. As a result, the cycle time can be greatly reduced to one or two hours, permitting several cycles to run per day.

As mentioned above, the Fmoc protecting group can be removed by use of bases such as ammonia, a primary amine or a secondary amine. (Note that Fmoc is stable to tertiary amines, such as triethylamine and diisopropylethylamine.) An advantage of using the base labile Fmoc group is that it eliminates the neutralization step of the deprotected non-side chain amino group, as is required when the t-butyloxycarbonyl ("Boc") protecting group is used. Thus, the addition of the next Fmoc-protected amino acid to the free amino

- 8 -

group readily proceeds and the cycle can be repeated to build the peptide chain.

The side chain protecting groups used in the present invention, in contrast to Fmoc, must be stable to 5 bases such as ammonia, a primary amine or a secondary amine, so that they remain intact under conditions when Fmoc is removed. Furthermore, after all protected amino acids have been linked together, the side chain protecting groups must also be readily removable by an 10 acid, e.g., trifluoroacetic acid, or by catalytic hydrogenation, e.g., when benzyl is used as the protecting group.

A side chain amino functionality, such as ϵ -amino of Lys, can be protected by Boc, carbobenzoxy, or 2- 15 chloro-carbobenzoxy.

A side chain carboxyl functionality, such as β -carboxyl of Asp, can be protected by t-butyl (ester), benzyl (ester), or cyclohexyl (ester). The same protecting groups can also be used to block the non-side 20 chain carboxyl functionality of the C-terminal amino acid.

A side chain hydroxyl functionality, such as that in Ser or Tyr, can be protected by t-butyl (ether) or benzyl (ether).

25 A side chain thiol functionality, such as that in Cys, can be protected by trityl (i.e., triphenylmethyl).

Other aspects of the present invention are well known in the art and will briefly discussed below.

30 Preparation of Peptides with Modification at the C-terminus

When a peptide with modification at the C-terminus is to be prepared, an amino acid derivative must be used in the first coupling reaction. The non-side chain functional group of the amino acid derivative can be

- 9 -

subjected to the coupling reaction either with or without protection.

For example, when the C-terminal residue is an amide or a substituted amide, an amino acid derivative
5 which is an amide or substituted amide can be introduced at the inception of the synthesis. This is because the amide or substituted amide functionalities are stable to the synthetic reagents.

As for peptides with a C-terminal ester, an amino
10 ester which is acid and base stable (i.e., benzyl esters) can also be introduced at the inception of the synthesis, if catalytic hydrogenation conditions, which are used to cleave benzyl esters, are not used in any of the subsequent deprotecting steps. On the other hand, amino
15 esters which are acid or base labile can be introduced at the inception of the synthesis only if they are stable to reagents used for the deprotection of the functionalities in the subsequent steps. Also, if an additional acidic functionality is present within the peptide sequence, the
20 corresponding protection group should be orthogonal.

Amino alcohols are stable to the synthetic reagents and can be introduced at the inception of the synthesis of a peptide alcohol. An ether linkage can also be used to promote stability or solubility, if
25 desired.

Scavengers

Scavengers react with the carbonium ions that can form when protecting groups are removed from the peptide. Amino acids containing aromatic rings are easily
30 alkylated or acylated by carbonium ions. Thus, it is preferable that scavengers be used at the deprotecting step. The carbonium ions present in the cleavage reaction can react with a scavenger or scavengers.

- 10 -

The types of scavengers to be used depend on the amino acids in the peptide. The most common scavengers are anisole, indole, phenol, water, mercaptoethanol, ethanedithiol, thiophenol, and dithiothreitol.

5 Neutralization

When a hydrochloride salt of the C-terminal amino acid (with its side chain functionality, if any, and its non-side chain carboxyl group protected) of the peptide to be synthesized is used, a strong base, such as
10 triethylamine or diisopropylethylamine, is first used to neutralize the non-side chain amino group before the coupling reaction. More specifically, the strong base forms a hydrochloride salt which is partially insoluble in the organic solvent used and can be removed by vacuum
15 filtration and aqueous extraction.

Similarly, when N-acylated peptide is to be prepared, it is preferable that a strong base be used to react with any acid produced from the acylation reaction, thereby preventing salt formation between the amino group
20 of the N-terminal amino acid with the acid.

Acylation

Acylation of the amino group of a peptide, either in the side chain or in the non-side chain, can be effected by an acid anhydride. For example, acetic
25 anhydride Ac_2O can be used for acetylation. Similarly, activated formic acid, such as mixed anhydrides (e.g., H-CO-O-CO-R , where R is H, CH_3 or CF_3) can be used for formylation. As another example, naphthoic acid or anhydride can be used to introduce a naphthoyl group to
30 the N-terminus of a peptide.

The coupling and deblocking reactions can be readily monitored by thin layer chromatography

- 11 -

("T.L.C."). The purity of the crude peptide, on the other hand, can be checked by either T.L.C. or high pressure liquid chromatography ("H.P.L.C."). The crude peptide can be further purified by H.P.L.C. and
5 lyophilized to give the peptide as a powder.

The continuous Fmoc solution method described above is a practical alternative to solid phase synthesis suitable for scale-up and is commercially attractive.

Without further elaboration, it is believed that a
10 person of ordinary skill in the art can, using the preceding description, utilize the present invention to its fullest extent. The two specific working examples provided below are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the
15 disclosure in any way whatsoever. For example, while α -amino acids are the building blocks in both examples, β - or γ -amino acids can also be used to prepare other peptides or derivatives thereof in an analogous fashion. By the same token, although peptide/peptide derivative
20 with a C-terminal carboxyl group were prepared in the working examples below, peptides with a C-terminal amide, ester or alcohol can be prepared in a similar manner with modifications well known in the art, e.g., see discussion above under the heading "Preparation of Peptides with
25 Modification at the C-terminus".

Below are the two T.L.C. systems which were used in the following working examples for monitoring the coupling reaction and the reaction of removing the protecting Fmoc group:

- 30 T.L.C. System One: methylene chloride:acetone 9:2,
 UV/ninhydrin
- T.L.C. System Two: n-butanol:acetic acid:water 4:1:1,
 UV/ninhydrin

- 12 -

EXAMPLE 1**Synthesis of Acetyl-Ser-Asp-Lys-Pro-OH**

Figure 1 shows the scheme followed to prepare Acetyl-Ser-Asp-Lys-Pro-OH.

5 A four liter Erlenmeyer flask equipped with magnetic stir bar was charged with 45.9 grams (0.221 moles) L-Proline-t-butyl ester hydrochloride, 113.9 grams (0.243 moles) of Fmoc-(BOC-L-Lysine) and 1.2 liters of methylene chloride. The suspension was stirred and 30.7
10 grams (0.243 moles) of diisopropylcarbodiimide and 22.4 grams (0.221 moles) of triethylamine were added. In this step, the amino group of Proline-t-butyl ester hydrochloride was neutralized by the added triethylamine (not shown in Figure 1). The mixture was stirred for 2
15 hours. T.L.C. (System One) indicated that the reaction was complete.

With the suspension being stirred, 441 mls (3.661 moles) of 4-aminomethylpiperidine was added and stirred for one hour. The suspension was filtered, the
20 precipitate was washed with portions of methylene chloride and the filtrate was diluted to a volume of 16 liters with methylene chloride. This solution was then washed with 3 x 8.0 liters (total of 24 liters) of 10% (w/v) phosphate buffer, pH 5.5. The methylene chloride
25 solution was dried over 300 grams sodium sulfate and T.L.C. (System Two) indicated completion of the reaction. The solution was vacuum filtered and concentrated to a volume of 0.9 liter. The mixture was vacuum filtered and the solid was washed with 3 x 0.1 liter of methylene
30 chloride. The volume of this solution was 1.2 liters.

This solution was stirred, 100.0 grams (0.243 moles) of Fmoc- β -(t-butyl)-L-Aspartic acid and 30.7 grams (0.243 moles) of diisopropylcarbodiimide were added. The mixture was stirred for 1 hour. T.L.C. (System One)
35 indicated that the reaction was complete.

- 13 -

- With the suspension being stirred, 441 mls (3.661 moles) of 4-aminomethylpiperidine was added and stirred for one hour. The suspension was vacuum filtered, the precipitate was washed with portions of methylene chloride and the filtrate was diluted to a volume of 16 liters with methylene chloride. This solution was washed with 3 x 8.0 liters (total of 24 liters) of 10% (w/v) phosphate buffer pH 5.5. The methylene chloride solution was dried over 300 grams of sodium sulfate and T.L.C. (System Two) indicated that the reaction was complete. The solution was vacuum filtered and concentrated to a volume of 0.9 liter. The mixture was vacuum filtered and the solid was washed with 3 x 0.1 liter of methylene chloride. The volume of this solution was 1.2 liters.
- This solution was stirred, 93.2 grams (0.243 moles) of Fmoc-O-(T-butyl)-L-Serine and 30.7 grams (0.243 moles) of diisopropylcarbodiimide were added. The mixture was stirred for 1 hour and T.L.C. (System One) indicated the reaction was complete.
- With the suspension being stirred, 441 mls (3.661 moles) of 4-aminomethylpiperidine was added and stirred for one hour. The suspension was vacuum filtered, the precipitate was washed with portions of methylene chloride and the filtrate was diluted to a volume of 16 liters with methylene chloride. This solution was washed with 3 x 8.0 liters (total of 24 liters) of 10% (w/v) phosphate buffer pH 5.5. The methylene chloride solution was dried over 300 grams of sodium sulfate and T.L.C. (System Two) indicated that the reaction was complete.
- The solution was vacuum filtered and concentrated to dryness.

The residue was dissolved in 0.3 liters of methylene chloride, vacuum filtered and solid was washed with 2 x 0.17 liter of methylene chloride.

- 14 -

The filtrate was stirred, 0.16 liter (1.695 moles) of acetic anhydride and 22.4 grams (0.221 moles) of triethylamine were added. The solution was stirred for 1 hour. T.L.C. (System Two) indicated the reaction was
5 complete. The solution was concentrated to an oily residue. The residue was triturated with 3 x 0.5 liters of diisopropyl ether. The solid was vacuum filtered and the white solid was dried to yield 119.3 grams (0.157 moles) of a white solid.

10 An Erlenmeyer flask equipped with magnetic stirrer was charged with 17.9 grams (0.023 moles) of the white solid and 0.179 liters of a 95% (v/v) solution of trifluoroacetic acid in methylene chloride was added. The solution was stirred for two hours and H.P.L.C. (95/5
15 0.1% trifluoroacetic acid/acetonitrile isocratic at 220 nm, 1.0 ml/min., 5 microns, C₁₈ column) indicated that the reaction was complete.

The solution was concentrated and the residue was triturated with 2 x 0.1 liter of diisopropyl ether. The
20 solid was vacuum filtered and dried to yield 10.46 grams of product (65% yield).

The crude product thus obtained was further purified by preparative H.P.L.C. The chromatogram of the purified product (with its corresponding peak denoted by
25 an asterisk) is shown in Figure 2.

EXAMPLE 2

Synthesis of H-Ser-Asp-Lys-Pro-OH

A 250 ml Erlenmeyer flask, equipped with magnetic stir bar, was charged with 1.44 grams (0.0069 moles) of
30 L-Proline t-butyl ester hydrochloride, 3.56 grams (0.0076 moles) of Fmoc-(ε-Boc-L-Lysine) and 37.6 mls of methylene chloride. The suspension was stirred and 0.96 grams (0.0076 moles) of diisopropylcarbodiimide and 0.70 grams (0.0069 moles) of triethylamine were added. The mixture

- 15 -

was stirred for 1 hour. T.L.C. (System One) indicated that the reaction was complete.

With the suspension being stirred, 13.8 mls (0.1146 moles) of 4-aminomethylpiperidine were added and stirred for one hour. The suspension was filtered, the precipitate was washed with portions of methylene chloride, and the filtrate was diluted to a volume of 500 mls with methylene chloride. This solution was washed with 3 x 250 mls (total of 750 mls) of 10% (w/v) phosphate buffer (pH 5.5). The methylene chloride solution was dried over 9.4 grams sodium sulfate and T.L.C. (System Two) indicated that the reaction was complete. The solution was vacuum filtered and concentrated to an oily residue. The residue was dissolved in 18.8 mls of methylene chloride, vacuum filtered and the solid was washed with 3 x 6.3 mls of methylene chloride. The volume of this solution was 37.6 mls.

This solution was stirred, 3.13 grams (0.0076 moles) of Fmoc- β -(t-butyl)-L-Aspartic acid and 0.960 grams (0.0076 moles) of diisopropylcarbodiimide were added. The mixture was stirred for 1 hour and T.L.C. (System One) indicated that the reaction was complete.

The suspension was stirred, 13.8 mls (0.1146 moles) of 4-aminomethylpiperidine were added and stirred for one hour. The suspension was vacuum filtered, the precipitate was washed with portions of methylene chloride, and the filtrate was diluted to a volume of 500 mls with methylene chloride. This solution was washed with 3 x 250 mls (total of 750 mls) of 10% (w/v) phosphate buffer (pH 5.5). The methylene chloride solution was dried over 9.4 grams sodium sulfate and T.L.C. (System Two) indicated that the reaction was complete. The solution was vacuum filtered, divided into halves and one half was concentrated to an oily residue.

- 16 -

(The remaining half of the solution was used in another experiment.) The residue was dissolved in 9.4 mls of methylene chloride, vacuum filtered and the solid was washed with 3 x 3.13 mls of methylene chloride. The
5 volume of this solution was 18.8 mls.

This solution was stirred, 1.46 grams (0.0038 moles) of Fmoc-O-(t-butyl)-L-Serine and 0.48 grams (0.0038 moles) of diisopropylcarbodiimide were added. The mixture was stirred for 1 hour and T.L.C. (System
10 One) indicated that the reaction was complete.

The suspension was stirred, 6.9 mls (0.0573 moles) of 4-aminomethylpiperidine were added and stirred for one hour. The suspension was vacuum filtered, the precipitate was washed with portions of methylene
15 chloride, and the filtrate was diluted to a volume of 250 mls with methylene chloride. This solution was washed with 3 x 125 mls (total of 375 mls) of 10% (w/v) phosphate buffer (pH 5.5). The methylene chloride solution was dried over 4.7 grams sodium sulfate and
20 T.L.C. (System Two) indicated that the reaction was complete. The solution was vacuum filtered and concentrated to an oily residue.

The oil was dissolved in 1 ml methylene chloride, 17.8 mls (0.231 moles) of trifluoroacetic acid were
25 added, and the mixture was stirred for two hours.

The solution was concentrated to an oil. The oil was triturated twice with 10 mls of diisopropyl ether, and the solid was dried. The solid was suspended in 10 mls of deionized water, 15 mls of aqueous 1 N acetic acid
30 was added and the solution was lyophilized to yield 1.52 grams of a crude product. A sample of the crude product was taken for H.P.L.C. (95/5 0.1% trifluoroacetic acid/acetonitrile isocratic at 220 nm 1.0 ml/min, 5 micron C₁₈ column). The result is shown in Figure 3 with

- 17 -

the peak corresponding to the peptide product denoted by an asterisk.

The overall yield of the crude product was estimated to be 82%. The crude product was further
5 purified by preparative H.P.L.C., the final yield being 53%.

The preceding examples can be repeated with success by substituting the generically or specifically described reactants and/or operating conditions of this
10 invention for those used in these examples. For instance, any peptide or its acyl derivative containing 2-10 amino acids can be prepared in a similar manner by consecutively coupling proper amino acids, followed by acylation with a proper acylating agent, if necessary.
15 When Cys is a building block of the peptide or its acyl derivative to be synthesized, an base-stable protecting group, such as triphenylmethyl, can be employed.

Also note that the reactants used in the present synthetic method are either commercially available or can
20 be readily prepared following procedures well known in the art of peptide synthesis.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and
25 scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

- 18 -

Claims

1. A continuous liquid phase synthetic method for preparing a peptide containing 2-10 amino acid residues with or without modification at the C-terminus
5 or an N-acyl derivative thereof, which method comprises the steps of:

(a) coupling a first amino acid or a derivative thereof to a second amino acid via an amide bond in an organic solvent containing a substituted carbodiimide,
10 with said first amino acid or derivative thereof having both its non-side chain carboxyl functionality and its side-chain functionalities, if any and necessary, blocked by base-stable groups and a second amino acid with its non-side chain amino functionality blocked by Fmoc and
15 its side chain functionalities, if any and necessary, blocked by base-stable groups;

(b) detaching said Fmoc with ammonia, a primary amine, or a secondary amine;

(c) coupling an additional amino acid to the Fmoc-
20 detached coupled product via an amide bond in an organic solvent containing a substituted carbodiimide, with said additional amino acid having its non-side chain amino functionality blocked by Fmoc and its side chain functionalities, if any and necessary, blocked by base-
25 stable groups;

(d) detaching said Fmoc with ammonia, a primary amine, or a secondary amine;

(e) repeating steps (c) and (d) until the length of said peptide or said N-acyl derivative is achieved;

30 (f) acylating the non-side chain amino group of the Fmoc-detached coupled product from the previous step; and

(g) detaching said base-stable groups;

wherein said first amino acid or derivative
35 thereof corresponds to a first residue or the C-terminal

- 19 -

residue in said peptide or said N-acyl derivative, said second amino acid corresponds to a second residue adjacent to the first residue in said peptide or said N-acyl derivative, and said additional amino acid
5 corresponds to a third residue adjacent to said second residue in said peptide or said N-acyl derivative; providing that when said peptide or said N-acyl derivative contains two amino acid residues, steps (c) through (e) are omitted; and further providing that when
10 said peptide, rather than said N-acyl derivative, is to be synthesized, step (f) is omitted.

2. The synthetic method of claim 1, wherein said organic solvent is methylene chloride, chloroform, or dichloroethane.

15 3. The synthetic method of claim 2, wherein said organic solvent is methylene chloride.

4. The synthetic method of claim 1, wherein said substituted carbodiimide is diisopropylcarbodiimide, dicyclohexylcarbodiimide, or N-ethyl-N'-(3-dimethyl-
20 aminopropyl)carbodiimide.

5. The synthetic method of claim 4, wherein said substituted carbodiimide is diisopropylcarbodiimide.

6. The synthetic method of claim 1, wherein said Fmoc is detached with 4-aminomethylpiperidine,
25 piperidine, or tris (2-aminoethyl) amine.

7. The synthetic method of claim 6, wherein said Fmoc is detached with 4-aminomethylpiperidine.

- 20 -

8. The synthetic method of claim 1, wherein said detached Fmoc is removed by filtration and subsequent washing with an acidic aqueous solution.

9. The synthetic method of claim 8, wherein said
5 acidic aqueous solution is a phosphate buffer.

10. The synthetic method of claim 8, wherein said organic solvent is methylene chloride and said Fmoc is detached with 4-aminomethylpiperidine.

11. The synthetic method of claim 1, wherein said
10 base-stable groups are detached with trifluoroacetic acid.

12. The synthetic method of claim 10, wherein said base-stable groups are detached with trifluoroacetic acid.

13. The synthetic method of claim 1, wherein said
15 N-acyl derivative is to be synthesized and a strong base is added in step (f).

14. The synthetic method of claim 13, wherein said strong base is triethylamine or
20 diisopropylethylamine.

15. The synthetic method of claim 1, wherein said peptide or said N-acyl derivative contains 3-7 amino acid residues.

16. The synthetic method of claim 15, wherein
25 said peptide or said N-acyl derivative contains 4 amino acid residues.

- 21 -

17. The synthetic method of claim 16, wherein said peptide or said N-acyl derivative is an N-acetyl derivative.

18. The synthetic method of claim 16, wherein
5 said peptide or said N-acetyl derivative is H-Ser-Asp-Lys-Pro-OH or Acetyl-Ser-Asp-Lys-Pro-OH.

19. The synthetic method of claim 18, wherein said base-stable protecting groups for Ser, Asp, Lys and Pro are t-butyl, t-butyl, t-butyloxycarbonyl, and t-
10 butyl, respectively.

20. The synthetic method of claim 18, wherein said organic solvent is methylene chloride, chloroform, or dichloroethane.

21. The synthetic method of claim 20, wherein
15 said organic solvent is methylene chloride.

22. The synthetic method of claim 18, wherein said substituted carbodiimide is diisopropylcarbodiimide, dicyclohexylcarbodiimide, or N-ethyl-N'-(3-dimethyl-aminopropyl)carbodiimide.

20 23. The synthetic method of claim 22, wherein said substituted carbodiimide is diisopropylcarbodiimide.

24. The synthetic method of claim 18, wherein said Fmoc is detached with 4-aminomethylpiperidine, piperidine, or tris (2-aminoethyl) amine.

25 25. The synthetic method of claim 24, wherein said Fmoc is detached with 4-aminomethylpiperidine.

- 22 -

26. The synthetic method of claim 18, wherein said detached Fmoc is removed by filtration and subsequent washing with an acidic aqueous solution.

27. The synthetic method of claim 26, wherein
5 said acidic aqueous solution is a phosphate buffer.

28. The synthetic method of claim 26, wherein said organic solvent is methylene chloride and said Fmoc is detached with 4-aminomethylpiperidine.

29. The synthetic method of claim 18, wherein
10 said base-stable groups are detached with trifluoroacetic acid.

30. The synthetic method of claim 29, wherein said base-stable groups are detached with trifluoroacetic acid.

15 31. The synthetic method of claim 18, wherein Acetyl-Ser-Asp-Lys-Pro-OH is to be synthesized and a strong base is added in step (f).

32. The synthetic method of claim 31, wherein said strong base is triethylamine or
20 diisopropylethylamine.

1/4






FIG. 1 (Page 1 of 2)

2/4



DIC = diisopropylcarbodiimide
 4-Amp = 4-aminomethylpiperidine
 Pi Buffer = 10% phosphate buffer, pH 5.5
 TEA = triethylamine
 TFA = trifluoroacetic acid
 tBu = t-butyl
 Boc = t-butyloxycarbonyl

FIG. 1 (page 2 of 2)

3/4




FIG. 2




FIG. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/05783

A. CLASSIFICATION OF SUBJECT MATTER				
IPC(5) :C07K 1/02, 1/06, 1/10, 3/04, 3/06 US CL :530/333, 338, 339, 341 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/333, 338, 339, 341				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US, A, 3,121,707 (ANDERSON) 18 FEBRUARY 1964. See column 2, lines 15-32, column 2, line 71 to column 3, line 27 and Examples 1-21.	1-32		
X	US, A, 3,769,271 (SOUTHARD) 30 OCTOBER 1973. See column 1, line 43 to column 2, line 17 and column 3, line 65 to column 6, line 19.	1-32		
A	US, A, 4,581,168 (DIAZ) 08 APRIL 1986. See the entire disclosure.	1-32		
A	US, A, 5,004,781 (RINK) 02 APRIL 1991. See the entire disclosure.	1-32		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be part of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "G" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be part of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "G" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be part of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "G" document member of the same patent family			
Date of the actual completion of the international search 23 AUGUST 1993		Date of mailing of the international search report OCT 04 1993		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE		Authorized officer NATHAN M. NUTTER <i>N M Nutter</i> Telephone No. (703) 308-2351		

Form PCT/ISA/210 (second sheet)(July 1992)*

BEST AVAILABLE COPY